These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 576511)

  • 1. Immunoelectrophoretic studies on the kinetics of plasmic degradation of human fibrinogen.
    Braude R; Altman R; Rouvier J; Aguilar N
    Thromb Haemost; 1977 Feb; 37(1):136-43. PubMed ID: 576511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunobiology of fibrinogen. Emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo.
    Plow E; Edgington TS
    J Clin Invest; 1973 Feb; 52(2):273-82. PubMed ID: 4119160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The half-life of plasmic degradation products of human fibrinogen in rabbits.
    Ardaillou N; Dray L; Budzynski AZ; Marder VJ; Larrieu MJ
    Thromb Haemost; 1977 Apr; 37(2):201-9. PubMed ID: 577624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmic degradation of fibrinogen Paris I.
    Budzynski AZ; Marder VJ
    J Lab Clin Med; 1976 Nov; 88(5):817-25. PubMed ID: 978044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunochemical discrimination of leukocyte elastase from plasmic degradation products of fibrinogen.
    Plow EF; Gramse M; Havemann K
    J Lab Clin Med; 1983 Dec; 102(6):858-69. PubMed ID: 6227673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
    Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
    Rinsho Byori; 1992 Jul; 40(7):789-94. PubMed ID: 1507499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
    Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
    Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN.
    Dempfle CE; Dollman M; Lill H; Puzzovio D; Dessauer A; Heene DL
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):79-86. PubMed ID: 8457657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The accelerating effect of fibrinogen and early fibrinogen degradation products on erythrocyte sedimentation.
    Marsh NA
    Thromb Haemost; 1979 Aug; 42(2):757-63. PubMed ID: 505378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Electrophoretic fractions and NH2-terminal amino acids of high-molecular tryptic fragments of fibrinogen and fibrin].
    Lugovskoĭ EV; Pozdniakova TM; Varetskaia TV; Derzskaia SG; Tolstykh VM
    Ukr Biokhim Zh; 1976; 48(6):743-9. PubMed ID: 1014141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenic activity of fibrin degradation products is located in fibrin fragment E.
    Thompson WD; Smith EB; Stirk CM; Marshall FI; Stout AJ; Kocchar A
    J Pathol; 1992 Sep; 168(1):47-53. PubMed ID: 1280677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests.
    Brenner B; Francis CW; Marder VJ
    J Lab Clin Med; 1989 Jun; 113(6):682-8. PubMed ID: 2732616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex-formation between the fibrin-derived plasmic fragments DD and E demonstrated by crossed immunoelectrophoresis.
    Gogstad GO; Brosstad F
    Thromb Res; 1983 Jun; 30(5):441-8. PubMed ID: 6225217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive exposure of E-neoantigen associated with degradation of crosslinked fibrin by plasmin in vitro.
    Stegnar M; Chen JP
    Thromb Haemost; 1984 Dec; 52(3):315-20. PubMed ID: 6241755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies.
    Raut S; Gaffney PJ
    Thromb Haemost; 1996 Jul; 76(1):56-64. PubMed ID: 8819252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of fibrinogen-antigenic material on the rheumatoid synovial membrane and in the rheumatoid synovial fluid.
    Clemmensen I; Andersen RB
    J Lab Clin Med; 1978 Nov; 92(5):678-89. PubMed ID: 712203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
    Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
    Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen fragments X, Y, D and E increase levels of plasma fibrinogen and liver mRNAs coding for fibrinogen polypeptides in rats.
    Princen HM; Moshage HJ; Emeis JJ; de Haard HJ; Nieuwenhuizen W; Yap SH
    Thromb Haemost; 1985 Apr; 53(2):212-5. PubMed ID: 4024030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catabolism of purified rat fibrin(ogen) plasmin degradation products in rats.
    Nieuwenhuizen W; Emeis JJ; Vermond A
    Thromb Haemost; 1982 Aug; 48(1):59-61. PubMed ID: 7135343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte suppressive peptides from fibrinogen are derived predominantly from the A alpha chain.
    Plow EF; Edgington TS
    J Immunol; 1986 Sep; 137(6):1910-5. PubMed ID: 2943807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.